Edwards Lifesciences Stock Surges On Heart Valve Devices Growth

Edwards Lifesciences Corp (NYSE:EW) shares are up on Friday as the company reported strong first-quarter results, highlighting growth in its transcatheter mitral and tricuspid therapies.

• Edwards Lifesciences stock is surging to new heights today. What’s behind EW gains?

Edwards Lifesciences Q1 Earnings Drive Stock Move

The heart devices company on Thursday reported quarterly adjusted earnings of 78 cents, beating the consensus of 73 cents. Sales reached $1.65 billion, beating the consensus of $1.59 billion.

Edwards Lifesciences announced a 16.7% year-over-year (+12.7% at constant currency) increase in sales for the first quarter, driven by robust demand for its heart valve therapies.

The company also noted significant growth in its transcatheter mitral and tricuspid procedures, further solidifying its position in the market.

Valve Therapies and TAVR Drive Growth

The company reported Transcatheter Aortic Valve Replacement (TAVR) sales of $1.2 billion, up 14.4% (+11%). SAPIEN growth in the U.S. was healthy, and it was even faster outside of the U.S.

Edwards’ global competitive position in the first quarter increased slightly year-over-year, mainly due to the exit of a competitor in Europe.

Transcatheter Mitral and Tricuspid Therapies (TMTT) sales of $173 million were driven by the company’s portfolio of repair and replacement therapies to treat mitral and tricuspid diseases.

Globally, mitral and tricuspid procedures grew in the estimated double digits, with Edwards’ sales growing at a higher rate.

Guidance Updated

Edwards Lifesciences raised its fiscal 2026 adjusted earnings per share from $2.90-$3.05 to $2.95-$3.05 compared to the consensus of $2.93.

It also widened 2026 sales guidance from $6.55 billion-$6.67 billion to $6.50 billion-$6.90 billion compared to the consensus estimate of $6.68 billion.

The company expects second-quarter adjusted earnings of 70 cents -76 cents compared to the consensus of 75 cents.

It forecasts sales between $1.66 billion and $1.74 billion compared to the consensus of $1.68 billion.

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with a consensus price target of $99.75. Recent analyst moves include:

• Evercore ISI Group: Outperform (Raises target to $93 on April 24)
• Baird: Neutral (Raises target to $87 on April 24)
• Cannacord: Hold (Lowers target to $85 on April 13)

How Edwards Lifesciences Ranks On Growth and Momentum

Below is the Benzinga Edge scorecard for Edwards Lifesciences, highlighting its strengths and weaknesses compared to the broader market:

• Value: 49.28 — The stock is trading at a moderate valuation relative to peers.
• Growth: 78.39 — Indicates strong growth potential.
• Quality: 56.2 — Reflects a solid balance sheet and operational efficiency.
• Momentum: 34.25 — Suggests weaker performance in recent trading.

The Verdict: Edwards Lifesciences’ Benzinga Edge signal reveals a growth-heavy profile, supported by strong sales growth in its innovative therapies. However, the momentum score indicates the stock may be facing some challenges in maintaining upward price movement.

EW Stock Price Activity: Edwards Lifesciences shares were up 4.58% at $83.37 at publication on Friday, according to Benzinga Pro data.

Image via Shutterstock